NCT04867330View on ClinicalTrials.gov

Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC

NARecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

May 31, 2021

Study Completion Date

January 31, 2026

Conditions
Oropharyngeal CarcinomaImmune Checkpoint InhibitorDe-escalation
Interventions
OTHER

Toxicities reduced treatment arm

Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)

Trial Locations (1)

200032

RECRUITING

Fudan Universtiy Shanghai Cancer Centre, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER